Research on bronchiectasis to improve personalized treatment
The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping. An EMBARC2 and EMBARC3 Study
This study is trying to find out more about different types of bronchiectasis in patients to see how personalized treatments can help them better manage their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Dundee Academic / other |
| Locations | 1 site (Dundee) |
| Trial ID | NCT03791086 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on bronchiectasis, a complex and heterogeneous lung disorder. It aims to identify different patient subgroups, known as phenotypes and endotypes, during stable disease and exacerbations. By analyzing clinical data, microbiological profiles, and inflammatory markers from up to 1000 patients, the study seeks to develop strategies for personalized medicine. The findings may help in validating biomarkers and identifying patient populations that could benefit from targeted treatments in future clinical trials.
Who should consider this trial
Good fit: Ideal candidates are adults with a confirmed diagnosis of bronchiectasis who have been clinically stable for at least four weeks.
Not a fit: Patients under 18 years of age or those with active tuberculosis or bronchiectasis due to cystic fibrosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment strategies for patients with bronchiectasis.
How similar studies have performed: Other studies have explored similar approaches in bronchiectasis, but this study aims to provide a more comprehensive understanding of the disease's heterogeneity.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and/or recurrent respiratory tract infections. * A primary diagnosis of bronchiectasis made by a respiratory physician * At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks. Exclusion Criteria: * Inability to give informed consent * \<18years of age * Patients with active tuberculosis * Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks * Bronchiectasis due to cystic fibrosis
Where this trial is running
Dundee
- University of Dundee — Dundee, United Kingdom (Recruiting)
Study contacts
- Principal investigator: James D Chalmers, MD, PhD — GSK/British Lung Foundation Chair of Respiratory Research
- Study coordinator: James D Chalmers, MD, PhD
- Email: james.chalmers@nhs.scot
- Phone: 01382660111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.